Department of Internal Medicine, McLaren/Michigan State University, Flint, MI, USA.
Cardiol Rev. 2013 Jan-Feb;21(1):42-8. doi: 10.1097/CRD.0b013e3182613db6.
Myocardial perfusion imaging is a well-established noninvasive modality for the diagnosis and prognosis of coronary artery disease. The pharmacologic stress agents adenosine and dipyridamole are widely used in imaging studies, but cause undesirable side effects, like atrioventricular block and bronchospasm, due to their nonselective adenosine receptor activation. Furthermore, the mode of administration of these agents as a bolus infusion is less preferred. Regadenoson, an A2A adenosine receptor selective pharmacologic stress agent was approved in 2008 and is widely used instead of adenosine and dipyridamole. This article reviews regadenosons structure, mechanism of action, advantages over adenosine and dipyridamole, and its role in various patient populations undergoing stress perfusion imaging. Emerging applications where regadenoson could be of potential use are also explored.
心肌灌注成像是一种用于诊断和预测冠状动脉疾病的成熟的非侵入性方法。药理学应激剂腺苷和双嘧达莫广泛应用于成像研究中，但由于其非选择性腺苷受体激活，会引起不良的副作用，如房室传导阻滞和支气管痉挛。此外，这些药物作为推注输注的给药方式不太受欢迎。雷卡地松是一种 A2A 腺苷受体选择性药理学应激剂，于 2008 年获得批准，广泛用于替代腺苷和双嘧达莫。本文综述了雷卡地松的结构、作用机制、与腺苷和双嘧达莫相比的优势，及其在各种进行应激灌注成像的患者群体中的作用。还探讨了雷卡地松可能具有潜在用途的新兴应用。
